Compare AstraZeneca plc (AZN) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Hut 8 Corp — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while Hut 8 Corp trades at $89.98 (market cap $10.94B). The key difference: AstraZeneca plc is far larger — about 22.7× Hut 8 Corp's market cap, and AstraZeneca plc pays a 2.01% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| AZN | HUT | |
|---|---|---|
Market Cap | $248.14B | $10.94B |
Sector | Health | Technology |
52-Week High | $209.48 | $133.02 |
52-Week Low | $147.06 | $21.37 |
Enterprise Value | $275.41B | $18.38B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
HUT trades at $93.91, up 9.63% today amid a broader neocloud stock rally. The stock shows bearish technical signals with support at $87 and resistance at $92. Fundamentally, revenue grew 81% year-over-year in Q2 2026 to $74 million, but net losses persist with a -188.59% margin. The company is transitioning to an AI data center focus, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (93.75%) and a $165.11 price target reflect optimism in AI infrastructure growth, but high valuation ratios and persistent losses pose risks. Execution on Beacon Point commercialization and debt management are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
